Overview

Immunosuppressant Medication Dosed Daily After Kidney Transplant

Status:
Terminated
Trial end date:
2020-11-27
Target enrollment:
Participant gender:
Summary
Medication non-adherence is a major risk factor for graft dysfunction and graft loss among pediatric and adult transplant recipients. Rates of non-adherence in these populations are estimated between 30 and 70%, with the highest prevalence in adolescent and young adult (AYA) transplant recipients. Treatment-related factors known to impact rates of adherence include the number of medication doses per day and the number of tablets or capsules a patient takes per day, or "pill burden". One approach to minimizing dosing frequency and pill-burden includes transitioning patients to once-daily formulations. The current literature investigating utilization of once-daily immunosuppressive regimens in the AYA kidney transplant population is limited.
Phase:
Early Phase 1
Details
Lead Sponsor:
University of Colorado, Denver
Treatments:
Tacrolimus